We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Committee to Examine Cardiovascular Risks of ADHD Drugs
FDA Committee to Examine Cardiovascular Risks of ADHD Drugs
January 13, 2006
An FDA advisory panel is convening next month to discuss clinical approaches that could be used to study potential cardiovascular risks associated with attention-deficit/hyperactivity disorder (ADHD) drugs.